Suppr超能文献

欧洲角膜基质内环形片段多中心研究的一年结果。第1部分:屈光结果。

One year results of European Multicenter Study of intrastromal corneal ring segments. Part 1: refractive outcomes.

作者信息

Ruckhofer J, Stoiber J, Alzner E, Grabner G

机构信息

Landesklinik für Augenheilkunde und Optometrie, Landeskliniken Salzburg, Austria.

出版信息

J Cataract Refract Surg. 2001 Feb;27(2):277-86. doi: 10.1016/s0886-3350(00)00749-5.

Abstract

PURPOSE

To assess the efficacy, predictability, stability, and safety of correcting myopia with intrastromal corneal ring segments (ICRS, KeraVision, Inc.).

SETTING

Twelve European investigational sites.

METHODS

Patients with myopia of -1.0 to -6.0 diopters (D) and best spectacle-corrected visual acuity (BSCVA) of 20/20 or better (except in 3 eyes) were assigned to receive 1 of 5 ICRS thicknesses (0.25, 0.30, 0.35, 0.40, or 0.45 mm). Efficacy was assessed by postoperative uncorrected visual acuity (UCVA), predictability of refractive outcome (deviation from predicted cycloplegic refraction spherical equivalent), and stability of refractive effect (manifest refraction spherical equivalent [MRSE]). Safety was assessed by maintenance or loss of preoperative BSCVA and induced manifest refraction cylinder. Measurements were made preoperatively and 1 and 7 days and 1, 2, 3, 6, and 12 months postoperatively.

RESULTS

One hundred fifty-nine ICRSs were implanted in the eyes of 107 patients (52 patients had bilateral implantation). Preoperatively, UCVA was worse than 20/40 in 98% of eyes (155/159); 12 months postoperatively, it was 20/20 or better in 63% of eyes (83/132) and 20/40 or better in 96% (127/132). Predicted refractive corrections for each ICRS thickness generally correlated with achieved corrections. At 12 months postoperatively, 90% of eyes (124/138) were within +/-1.00 D of plano (MRSE). Two or more lines of BSCVA were lost in 6% of eyes (8/135); all 8 eyes had BSCVAs of 20/25 or better.

CONCLUSION

The ICRS safely, effectively, and predictably reduced or eliminated low to moderate myopia. Refractive correction was stable through the 12 month follow-up.

摘要

目的

评估使用基质内角膜环片(ICRS,KeraVision公司)矫正近视的疗效、可预测性、稳定性及安全性。

设置

12个欧洲研究地点。

方法

将近视度数为-1.0至-6.0屈光度(D)且最佳矫正视力(BSCVA)为20/20或更佳(3只眼除外)的患者分配接受5种ICRS厚度(0.25、0.30、0.35、0.40或0.45毫米)中的一种。通过术后裸眼视力(UCVA)、屈光结果的可预测性(与预测的睫状肌麻痹验光球镜等效度的偏差)以及屈光效果的稳定性(显验光球镜等效度[MRSE])评估疗效。通过术前BSCVA的维持或丧失以及诱导的显验光柱镜评估安全性。术前以及术后1天、7天、1个月、2个月、3个月、6个月和12个月进行测量。

结果

107例患者(52例患者为双眼植入)的眼内植入了159片ICRS。术前,98%的眼(155/159)的UCVA低于20/40;术后12个月,63%的眼(83/132)的UCVA为20/20或更佳,96%(127/132)为20/40或更佳。每种ICRS厚度的预测屈光矫正通常与实际矫正相关。术后12个月,90%的眼(124/138)的MRSE在±1.00 D的平光范围内。6%的眼(8/135)丧失了两行或更多行的BSCVA;所有8只眼的BSCVA均为20/25或更佳。

结论

ICRS安全、有效且可预测地降低或消除了低度至中度近视。在12个月的随访期间屈光矫正稳定。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验